Enhancing Bone Health: Exploring the Role of Synbiotic Therapy

Explore cutting-edge research and innovative strategies for reducing bone loss with a focus on the gut-bone axis. In this webinar, leading experts Susan Bukata, MD, Chair of Orthopaedic Surgery, UCSD and Mark Charbonneau, PhD, Vice President of Research and Development of Journa, will discuss recent advancements in gut health and their implications for managing bone health in clinical settings.

Discover how enhancing gut barrier function, reducing systemic inflammation, and targeting osteoclast activity with Bondia^TM (SBD111), a novel synbiotic medical food, can improve outcomes for patients at risk of bone loss.

Objectives:

• Examine the connection between gut health, systemic inflammation, and bone metabolism
• Review findings from the SBD111 clinical food trial in postmenopausal women, highlighting its role in maintaining bone mass and reducing bone resorption
• Explore how Bondia^TM (SBD111) supports bone health through its impact on gut barrier function, systemic inflammation, and osteoclast activity
• Learn how to apply emerging evidence on gut-bone axis in clinical settings to improve outcomes for patients with bone health concerns

Speakers

Susan Bukata, MD, Chair of Orthopaedic Surgery, University of California San Diego

Susan Bukata, MD, is a board-certified orthopedic surgeon internationally recognized for her expertise in bone fragility disorders, including osteoporosis and rare genetic bone diseases. Her NIH-funded research focuses on accelerating fracture healing and reducing the need for additional surgical intervention. Dr. Bukata has published extensively in leading scientific journals and holds a patent for cartilage and musculoskeletal soft tissue repair technology. She serves on several prominent boards, including the Orthopaedic Research Society Executive Board, and has been named a "Top Doctor" by Castle Connolly and other organizations. She completed advanced training in orthopedic oncology and metabolic bone disease at Memorial Sloan Kettering Cancer Center.

Mark Charbonneau, PhD, Vice President of Research and Development, Journa pioneered by Solarea Bio

Mark obtained his Ph.D. in Computational and Systems Biology in the laboratory of Jeffrey I. Gordon at Washington University in St Louis, studying the interactions between infant gut microbial communities and growth in animal models of undernutrition. Mark has over a decade of experience in microbiome research, bioinformatics and live biotherapeutic development and a passion for advancing biotechnology solutions that leverage the microbiome to improve human health and nutrition. This work led him to join Journa, pioneered by Solarea Bio, a consumer health brand focused on scientific innovation that benefits patient health.

Thank you for downloading!

Download Now